FDA finally approves Reata’s rare genetic disease drug – Endpoints News

1. FDA finally approves Reata’s rare genetic disease drug Endpoints News
2. FDA Widens Path for Rare-Disease Treatments With New Approval The Wall Street Journal
3. RETA Stock Skyrockets As FDA Approves Reata Phama’s Neurological Drug | Investor’s Business Daily Investor’s Business Daily
4. Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s Ataxia Business Wire
5. FDA approves Reata’s treatment for rare neurological disease STAT
6. View Full Coverage on Google News

Read original article here